CO6160295A2 - Derivados de benzazepina utiles como antagonistas de vasopresina - Google Patents
Derivados de benzazepina utiles como antagonistas de vasopresinaInfo
- Publication number
- CO6160295A2 CO6160295A2 CO10007691A CO10007691A CO6160295A2 CO 6160295 A2 CO6160295 A2 CO 6160295A2 CO 10007691 A CO10007691 A CO 10007691A CO 10007691 A CO10007691 A CO 10007691A CO 6160295 A2 CO6160295 A2 CO 6160295A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- optionally substituted
- hydroxy
- dioxol
- oxo
- Prior art date
Links
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical class N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- -1 benzazepine compound Chemical class 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000004526 pharmaceutical effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001256 tolvaptan Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007167207 | 2007-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6160295A2 true CO6160295A2 (es) | 2010-05-20 |
Family
ID=39773045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10007691A CO6160295A2 (es) | 2007-06-26 | 2010-01-26 | Derivados de benzazepina utiles como antagonistas de vasopresina |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8669229B2 (enExample) |
| EP (3) | EP2374798B1 (enExample) |
| JP (3) | JP5653043B2 (enExample) |
| KR (1) | KR101487201B1 (enExample) |
| CN (3) | CN101687805A (enExample) |
| AR (1) | AR067176A1 (enExample) |
| AT (1) | ATE545633T1 (enExample) |
| AU (1) | AU2008269918B2 (enExample) |
| BR (1) | BRPI0813768A2 (enExample) |
| CA (1) | CA2690335A1 (enExample) |
| CO (1) | CO6160295A2 (enExample) |
| CY (3) | CY1113519T1 (enExample) |
| DK (3) | DK2374798T3 (enExample) |
| ES (3) | ES2380085T3 (enExample) |
| HR (3) | HRP20120310T1 (enExample) |
| IL (1) | IL202561A0 (enExample) |
| MY (3) | MY148312A (enExample) |
| NZ (3) | NZ598064A (enExample) |
| PH (2) | PH12012501363A1 (enExample) |
| PL (3) | PL2374798T3 (enExample) |
| PT (3) | PT2374797E (enExample) |
| RU (1) | RU2471784C2 (enExample) |
| SG (2) | SG182230A1 (enExample) |
| SI (3) | SI2374797T1 (enExample) |
| TW (1) | TWI459947B (enExample) |
| UA (1) | UA98966C2 (enExample) |
| WO (1) | WO2009001968A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI459947B (zh) * | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
| JP5656399B2 (ja) * | 2008-12-26 | 2015-01-21 | 大塚製薬株式会社 | 医薬及び医薬製剤 |
| CN102030709B (zh) * | 2009-09-25 | 2013-10-16 | 江苏豪森医药集团有限公司 | 用作加压素受体拮抗剂的苯并氮杂卓类化合物 |
| JP5717645B2 (ja) * | 2009-10-26 | 2015-05-13 | 大塚製薬株式会社 | ベンズアゼピン化合物 |
| GB201105537D0 (en) | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN102260213B (zh) * | 2011-05-31 | 2013-05-15 | 重庆福安药业(集团)股份有限公司 | 一种托伐普坦的制备方法 |
| TWI704919B (zh) | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| EP2941242B1 (en) * | 2012-12-28 | 2017-02-01 | Otsuka Pharmaceutical Co., Ltd. | Injectable depot formulation comprising optically active tolvaptan and process of producing the same |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| TWI660748B (zh) * | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 |
| TW201605488A (zh) | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| US11911369B2 (en) * | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
| WO2019003433A1 (ja) * | 2017-06-30 | 2019-01-03 | 大塚製薬株式会社 | ベンゾアゼピン誘導体 |
| CN107540672A (zh) * | 2017-10-10 | 2018-01-05 | 牡丹江医学院 | 一种治疗肝硬化的药物及其合成方法 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| CN112851583B (zh) * | 2021-01-19 | 2023-09-08 | 徐州医科大学 | 新型苯并氮杂䓬类化合物、组合物及其用途 |
| KR20230143165A (ko) * | 2021-02-10 | 2023-10-11 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 벤즈아제핀 화합물, 이의 제조 방법 및 이의 약학적 용도 |
| CN113112528A (zh) * | 2021-04-26 | 2021-07-13 | 中南财经政法大学 | 异常行为监控方法、装置、设备及存储介质 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5045478A (en) * | 1986-03-03 | 1991-09-03 | Becton Dickinson And Company | Vesicles and use thereof in an assay |
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| EP0602209A1 (en) | 1992-07-02 | 1994-06-22 | Otsuka Pharmaceutical Co., Ltd. | Oxytocin antagonist |
| TW270927B (enExample) * | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| GB9726695D0 (en) | 1997-12-17 | 1998-02-18 | Smithkline Beecham Plc | Novel compounds |
| JP4210355B2 (ja) | 1997-07-03 | 2009-01-14 | 大塚製薬株式会社 | 固形製剤組成物 |
| EA004436B1 (ru) * | 1998-09-29 | 2004-04-29 | Уайт Холдингз Корпорейшн | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ |
| DE60102815D1 (de) | 2000-05-15 | 2004-05-19 | Paratek Pharm Innc | 7-substituierte kondensierte ring-tetrazyclin- verbindungen |
| BRPI0516922A (pt) * | 2004-11-02 | 2008-09-23 | New River Pharmaceuticals Inc | composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica |
| CA2633929A1 (en) * | 2005-12-27 | 2007-07-05 | Otsuka Pharmaceutical Co., Ltd. | Water-soluble benzoazepine compound and its pharmaceutical composition |
| TWI459947B (zh) * | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
-
2008
- 2008-06-24 TW TW097123513A patent/TWI459947B/zh active
- 2008-06-26 UA UAA201000653A patent/UA98966C2/ru unknown
- 2008-06-26 SG SG2012047056A patent/SG182230A1/en unknown
- 2008-06-26 AR ARP080102749A patent/AR067176A1/es unknown
- 2008-06-26 JP JP2009553349A patent/JP5653043B2/ja not_active Expired - Fee Related
- 2008-06-26 SI SI200831177T patent/SI2374797T1/sl unknown
- 2008-06-26 EP EP11172829.1A patent/EP2374798B1/en not_active Not-in-force
- 2008-06-26 PT PT111728283T patent/PT2374797E/pt unknown
- 2008-06-26 EP EP08765871A patent/EP2170831B1/en not_active Not-in-force
- 2008-06-26 MY MYPI20095341A patent/MY148312A/en unknown
- 2008-06-26 CA CA2690335A patent/CA2690335A1/en not_active Abandoned
- 2008-06-26 DK DK11172829.1T patent/DK2374798T3/da active
- 2008-06-26 PL PL11172829T patent/PL2374798T3/pl unknown
- 2008-06-26 MY MYPI20124513 patent/MY152805A/en unknown
- 2008-06-26 NZ NZ598064A patent/NZ598064A/xx not_active IP Right Cessation
- 2008-06-26 DK DK08765871.2T patent/DK2170831T3/da active
- 2008-06-26 PT PT08765871T patent/PT2170831E/pt unknown
- 2008-06-26 US US12/666,751 patent/US8669229B2/en not_active Expired - Fee Related
- 2008-06-26 MY MYPI20124514 patent/MY150941A/en unknown
- 2008-06-26 WO PCT/JP2008/062033 patent/WO2009001968A1/en not_active Ceased
- 2008-06-26 PH PH1/2012/501363A patent/PH12012501363A1/en unknown
- 2008-06-26 CN CN200880022253A patent/CN101687805A/zh active Pending
- 2008-06-26 AT AT08765871T patent/ATE545633T1/de active
- 2008-06-26 ES ES08765871T patent/ES2380085T3/es active Active
- 2008-06-26 SI SI200831051T patent/SI2374798T1/sl unknown
- 2008-06-26 CN CN2013101949565A patent/CN103342680A/zh active Pending
- 2008-06-26 DK DK11172828.3T patent/DK2374797T3/da active
- 2008-06-26 PL PL08765871T patent/PL2170831T3/pl unknown
- 2008-06-26 ES ES11172828.3T patent/ES2460018T3/es active Active
- 2008-06-26 CN CN2013101948844A patent/CN103342679A/zh active Pending
- 2008-06-26 KR KR20107001719A patent/KR101487201B1/ko not_active Expired - Fee Related
- 2008-06-26 RU RU2010102229/04A patent/RU2471784C2/ru not_active IP Right Cessation
- 2008-06-26 NZ NZ598067A patent/NZ598067A/xx not_active IP Right Cessation
- 2008-06-26 HR HRP20120310AT patent/HRP20120310T1/hr unknown
- 2008-06-26 EP EP11172828.3A patent/EP2374797B1/en not_active Not-in-force
- 2008-06-26 PH PH1/2012/501362A patent/PH12012501362A1/en unknown
- 2008-06-26 SI SI200830557T patent/SI2170831T1/sl unknown
- 2008-06-26 SG SG2012047064A patent/SG182231A1/en unknown
- 2008-06-26 AU AU2008269918A patent/AU2008269918B2/en not_active Ceased
- 2008-06-26 NZ NZ581723A patent/NZ581723A/en not_active IP Right Cessation
- 2008-06-26 BR BRPI0813768-4A2A patent/BRPI0813768A2/pt not_active IP Right Cessation
- 2008-06-26 ES ES11172829T patent/ES2431515T3/es active Active
- 2008-06-26 PT PT111728291T patent/PT2374798E/pt unknown
- 2008-06-26 PL PL11172828T patent/PL2374797T3/pl unknown
-
2009
- 2009-12-07 IL IL202561A patent/IL202561A0/en unknown
-
2010
- 2010-01-26 CO CO10007691A patent/CO6160295A2/es unknown
-
2012
- 2012-05-04 CY CY20121100415T patent/CY1113519T1/el unknown
-
2013
- 2013-09-24 US US14/034,943 patent/US8785386B2/en not_active Expired - Fee Related
- 2013-09-24 US US14/034,979 patent/US9073868B2/en not_active Expired - Fee Related
- 2013-10-10 CY CY20131100894T patent/CY1114491T1/el unknown
- 2013-11-18 HR HRP20131095AT patent/HRP20131095T1/hr unknown
-
2014
- 2014-05-30 HR HRP20140501AT patent/HRP20140501T1/hr unknown
- 2014-06-11 CY CY20141100426T patent/CY1115226T1/el unknown
- 2014-06-25 JP JP2014130326A patent/JP5689195B2/ja not_active Expired - Fee Related
- 2014-06-25 JP JP2014130327A patent/JP5893085B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6160295A2 (es) | Derivados de benzazepina utiles como antagonistas de vasopresina | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20090905A1 (es) | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| CO5580779A2 (es) | Pirimidinonas como receptor 1 de la hormona concentradora de la melanina | |
| EA201171387A1 (ru) | Производные 7-азаспиро[3,5]нонан-7-карбоксилатов, их получение и их применение в терапии | |
| CO5700742A2 (es) | Moduladores del receptor de quimioquina ccr5 | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| AR045955A1 (es) | Compuestos benzoimidazolicos | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| DOP2010000226A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
| AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
| CO6260009A2 (es) | Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas | |
| PE20120900A1 (es) | Compuestos heterociclicos de fenoximetilo | |
| AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| CO6160324A2 (es) | Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario | |
| GB0507601D0 (en) | Compounds | |
| AR069387A1 (es) | Compuestos de cicloalquiloxi -y heterocicloalquiloxipiridina como moduladores del receptor de histamina h3 |